Abingdon Health PLC (ABDX.L) Update on AffiDX® SARS-CoV-2 antigen LFT

Technical transfer completed mid-December as planned

Sales of AffiDX® paused by Avacta following Omicron sensitivity analysis

York, U.K. 10 January 2022: Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, provides the following update on Avacta Group plc’s (“Avacta”) AffiDX® SARS-CoV-2 antigen lateral flow test:

Completion of Technical Transfer

Abingdon confirms that it completed the technical transfer of the AffiDX® SARS-CoV-2 antigen lateral flow test assay product as planned. Technical transfer is the process of taking a developed product and optimising all processes and elements for mass manufacture. The final technical transfer batches were shipped to Avacta in mid-December 2021 with the products adhering to defined specifications and passing all quality control procedures.

Sensitivity of AffiDX® SARS-CoV-2 antigen lateral flow test

Abingdon also notes the announcement from Avacta this morning in relation to their AffiDX® SARS-CoV-2 antigen lateral flow test, which highlights that the sensitivity of the test is reduced at lower viral loads when identifying the Omicron variant, compared to the test’s sensitivity with previous variants. The Company understands this is a characteristic reported for other lateral flow tests already on the market.

The Company notes that Avacta’s Affimer® reagent in the AffiDX® test detects the Omicron variant with the same sensitivity as the Delta variant, and that it is the performance of the antibody, which pairs with the Affimer® in the test, that has been affected by the additional Omicron mutations. The Company also notes that Avacta has independently taken the decision to pause sales of the AffiDX® antigen test whilst it replaces the antibody in the product to ensure that its performance with the Omicron variant matches the high performance with previous mutations.

Abingdon scientists will work with Avacta to accelerate the process of replacing the antibody in the current assay format, and complete the process of technology transfer with this new specification.

COVID-19 Antigen Testing Products

The Company has two projects in COVID-19 antigen testing. These two projects involve the scale-up and technical transfer to manufacture for the AffiDX® SARS-CoV-2 antigen lateral flow test and for the Vatic KnowNow™ rapid antigen test developed by Vatic Health Limited which uses a saliva sample. The process of technical transfer for the Vatic KnowNow™ rapid antigen test remains on track with completion anticipated during calendar Q1 2022. According to Vatic the KnowNowᵀ test mimics the means through which the virus interacts with the surface of a human cell in order to detect it. As a result, they expect that it will continue to identify the SARS-CoV-2 virus even in the face of further potential mutations in the future.

Abingdon also has a pipeline of other non-COVID-19 contract service opportunities that it will seek to bring through technical transfer and into manufacture in due course.


Abingdon Health plc


Chris Yates, Chief Executive Officer

Via Walbrook PR

Melanie Ross , Chief Financial Officer

Christopher Hand, Non-Executive Chairman

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.